Effects of proteasome inhibitor, MG132, on proteasorne activity and oxidative status of rat liver

被引:22
|
作者
Alexandrova, Alberta [1 ]
Petrov, Lubomir [1 ]
Georgieva, Almira [1 ]
Kirkova, Margarita [1 ]
Kukan, Marian [2 ]
机构
[1] Bulgarian Acad Sci, Inst Neurobiol, BU-1113 Sofia, Bulgaria
[2] Slovak Med Univ, Slovak Ctr Organ Tranplantat, Lab Perfused Organs, Bratislava, Slovakia
关键词
MG132; proteasome; lipid peroxidation; protein oxidation; antioxidant enzyme activities; rat liver;
D O I
10.1002/cbf.1459
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
In vivo effects of N-benzyloxycarbonyl (Cbz)-Leu-Leu-leucinal (MG132) on chymotryptic-like (ChT-L), tryptic-like, and post-glutamyl peptide hydrolytic-like proteasome activities, protein oxidation, lipid peroxidation (LP), glutathione (GSH) level, as well as on the activity of antioxidant enzymes (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), and glutathione-reductase) in the rat liver were studied. The possibility of MG132 provoking the formation of free oxygen radicals was also assayed in primary hepatocytes. The following results were obtained: (1) In vivo, MG132 did not change the spontaneous LP, but increased Fe-induced LP and the amount of oxidized proteins; it decreased the GSH level in liver. From the proteasome activities studied in liver cytosol only ChT-L activity was significantly decreased after MG132 administration. Furthermore, MG132 increased antioxidant enzyme activities of SOD, CAT, and GSH-Px. (2) In vitro, MG132 increased free radical oxygen species in hepatocytes; this effect disappeared in the presence of CAT or mannitol. In conclusion, since nowadays proteasome inhibitors are entering into the swing of laboratory and clinical practice, the present data could provide useful information for MG132 action. Consequently, future in vivo experiments with MG132 could highlight the possibility of its use at different pathological conditions. Copyright (c) 2008 John Wiley & Sons, Ltd.
引用
收藏
页码:392 / 398
页数:7
相关论文
共 50 条
  • [1] Effect of MG132 on proteasome activity and prooxidant/antioxidant status of rat liver subjected to ischemia/reperfusion injury
    Alexandrova, Albena
    Petrov, Lubomir
    Georgieva, Almira
    Kessiova, Mila
    Tzvetanova, Elina
    Kirkova, Margarita
    Kukan, Marian
    HEPATOLOGY RESEARCH, 2008, 38 (04) : 393 - 401
  • [2] Effect of proteasome inhibitor MG132 on the expression of oxidative metabolism related genes in tomato
    Karpuz, Burcu
    Cakir, Ozgur
    FOOD SCIENCE AND TECHNOLOGY, 2022, 42
  • [3] PREVENTION OF MUSCLE DISUSE ATROPHY BY MG132 PROTEASOME INHIBITOR
    Jamart, Cecile
    Raymackers, Jean-Marc
    An, Gang Li
    Deldicque, Louise
    Francaux, Marc
    MUSCLE & NERVE, 2011, 43 (05) : 708 - 716
  • [4] MG132, a proteasome inhibitor, induces apoptosis in tumor cells
    Guo, Na
    Peng, Zhilan
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2013, 9 (01) : 6 - 11
  • [5] The proteasome inhibitor MG132 protects against acute pancreatitis
    Letoha, T
    Somlai, C
    Takács, T
    Szabolcs, A
    Rakonczay, Z
    Jármay, K
    Szalontai, T
    Varga, I
    Kaszaki, J
    Boros, I
    Duda, E
    Hackler, L
    Kurucz, I
    Penke, B
    FREE RADICAL BIOLOGY AND MEDICINE, 2005, 39 (09) : 1142 - 1151
  • [6] The role of proteasome inhibitor MG132 in cisplatin resistant ovarian cancer
    Zhang, Bailing
    Guo, Na
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2023, 44 (04) : 28 - 36
  • [7] Proteasome inhibitor MG132 inhibits the process of renal interstitial fibrosis
    Han, Lin
    Zhu, Bingbing
    Chen, Hui
    Jin, Yuanmeng
    Liu, Jian
    Wang, Weiming
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2019, 17 (04) : 2953 - 2962
  • [8] Systemic Perturbation of the ERK Signaling Pathway by the Proteasome Inhibitor, MG132
    Cirit, Murat
    Grant, Kyle G.
    Haugh, Jason M.
    PLOS ONE, 2012, 7 (11):
  • [10] The effect of proteasome inhibitor MG132 on experimental inflammatory bowel disease
    Inoue, S.
    Nakase, H.
    Matsuura, M.
    Mikami, S.
    Ueno, S.
    Uza, N.
    Chiba, T.
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2009, 156 (01): : 172 - 182